Literature DB >> 11321729

[Histological characteristics and prevalence of secondary osteoporosis in systemic mastocytosis. A retrospective analysis of 158 cases].

G Delling1, H Ritzel, M Werner.   

Abstract

Mastocytosis is characterized by abnormal proliferation of mast cells especially within the skin and bone marrow and is often associated with osteoporosis. Mast cells can synthesize a variety of cytokines that are known to affect the skeletal system, but the cellular and pathophysiological mechanisms leading to osteoporosis in systemic mastocytosis remain poorly understood. To further characterize mastocytosis-associated osteoporosis we compared bone histomorphometric findings in iliac crest biopsy specimens from 158 untreated patients with mastocytosis. The overall prevalence of mastocytosis in the specimens diagnosed with osteoporosis was 1.25%, but that in patients younger than 45 years was 2.25%. The male-to-female ratio was 1:1, in contrast to 1:2 in osteoporosis. Osteopenia was present in 64% of the patients with mastocytosis, while osteosclerosis was rare (3%). Histological criteria are the concentric increase in mast cells in the perivascular tissue and the increase in elongated mast cells within the marrow space. Histomorphometry showed mastocytosis to be associated with moderate hyperosteoidosis and increased perforating bone resorption, indicated by a significant decrease in bone volume, trabecular thickness, and trabecular number as compared to controls. Osteoclast number was not altered, pointing to a functional effect of mast cells and/or its product on osteoclasts, rather than an effect on osteoclast differentiation. We conclude that although the prevalence of mastocytosis seems to be low, its correct and early diagnosis is crucial for at least 2.25% of younger patients with osteoporosis.

Entities:  

Mesh:

Year:  2001        PMID: 11321729     DOI: 10.1007/s002920000439

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  9 in total

Review 1.  [Systemic mastocytosis--definition of an internal disease].

Authors:  Jürgen Homann; Ulrich W Kolck; Andreas Ehnes; Thomas Frieling; Martin Raithel; Gerhard J Molderings
Journal:  Med Klin (Munich)       Date:  2010-09-08

2.  Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis.

Authors:  S Seitz; F Barvencik; T Koehne; M Priemel; P Pogoda; J Semler; H Minne; M Pfeiffer; J Zustin; K Püschel; C Eulenburg; T Schinke; M Amling
Journal:  Osteoporos Int       Date:  2013-02-23       Impact factor: 4.507

Review 3.  Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.

Authors:  M Rossini; R Zanotti; G Orsolini; G Tripi; O Viapiana; L Idolazzi; A Zamò; P Bonadonna; V Kunnathully; S Adami; D Gatti
Journal:  Osteoporos Int       Date:  2016-02-18       Impact factor: 4.507

4.  Systemic mastocytosis with skeletal involvement: a case report and review of the literature.

Authors:  Maurizio Benucci; Catia Bettazzi; Stefania Bracci; Plinio Fabiani; Laura Monsacchi; Carlo Cappelletti; Mariangela Manfredi; Stefania Ciolli
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

5.  Hypertryptasemia and Mast Cell-Related Disorders in Severe Osteoporotic Patients.

Authors:  Giulia Carosi; Gregorio Guabello; Matteo Longhi; Federica Grifoni; Elena Passeri; Sabrina Corbetta
Journal:  Mediators Inflamm       Date:  2020-10-20       Impact factor: 4.711

6.  [Severe therapy refractive osteoporosis : A rare differential diagnosis].

Authors:  M Gehlen; A D Lazarescu; C Hinz; N Schmidt; M Pfeifer; M Werner; H F Weidemann; M Schwarz-Eywill; A Maier
Journal:  Z Rheumatol       Date:  2016-09       Impact factor: 1.372

7.  Osteoporosis Caused by Systemic Mastocytosis: Prevalence in a Cohort of 8392 Patients with Osteoporosis.

Authors:  Martin Gehlen; Niels Schmidt; Michael Pfeifer; Subathira Balasingam; Michael Schwarz-Eywill; Anna Maier; Mathias Werner; Heide Siggelkow
Journal:  Calcif Tissue Int       Date:  2021-07-05       Impact factor: 4.333

8.  Systemic mastocytosis presenting as osteoporosis--a case report.

Authors:  R Mathew; V Dhillon; P Shepherd
Journal:  Clin Rheumatol       Date:  2009-03-21       Impact factor: 2.980

9.  Alendronate promotes osteoblast differentiation and bone formation in ovariectomy-induced osteoporosis through interferon-β/signal transducer and activator of transcription 1 pathway.

Authors:  Xiaoqing Ma; Zhongyang Xu; Shaofeng Ding; Guangkun Yi; Qian Wang
Journal:  Exp Ther Med       Date:  2017-10-27       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.